Article
Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.
Journal of clinical pharmacy and therapeutics - 1 Jun 2016
Zhou L-Y, Zuo X-C, Chen K, Wang J-L, Chen Q-J, Zhou Y-N, Yuan H, Ma Y, Zhu L-J, Peng Y-X, Ming Y-Z
Abstract excerpt
WHAT IS KNOWN AND OBJECTIVE: The calcium channel blocker diltiazem has been used widely as a cyclosporine (CsA)/tacrolimus-sparing agent. However, considerable interpatient variability in diltiazem's CsA/tacrolimus-sparing effect has been observed in many clinical studies. This study was carried out to investigate the impacts of the CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the trough concentration/dose...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.